2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
… 2023 Additional pivotal trial recommended by EMA for sepofarsen prior to a regulatory submission Company will seek … – including Illuminate , Insight , and Brighten for sepofarsen, along with Sirius and Helia for ultevursen – will …
… Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen … data from our InSight extension study supporting sepofarsen’s potential to treat patients with LCA10 and … to provide updated guidance for timelines in the fall. Sepofarsen, lead clinical candidate for Leber congenital …
… Financial Results Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data … for adRP, data from the Phase 1/2 extension study of sepofarsen, and to start dosing patients with QR-504a for …
… and Financial Results Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; … retinal diseases.” Business Operations and Program Updates Sepofarsen, lead clinical candidate for Leber congenital …
… strategy, which includes starting the Phase 2/3 trial for sepofarsen in LCA10 patients, initiating the first-in-human … (PRIME) program by the European Medicines Agency (EMA) for sepofarsen. The PRIME program is particularly focused on …
… retinal diseases (IRDs). The positive interim data for sepofarsen in LCA10 has resulted in our ability to move … blindness.” Corporate Highlights and Business Update Sepofarsen (formerly QR-110) for LCA10 In January 2019, …
